Clinical Immunology

Clinical immunology: The new immunotherapies

This year’s HOT TOPIC focuses on “Clinical immunology: The new immunotherapies“, for the practising dermatologist.  32 of Europe’s leading immunologists will teach us clinicians what we need to know about allergic, autoimmune and auto-inflammatory diseases, immune-deficiencies, as well as the immunotherapies of infectious and malignant diseases.

Below is a preview of the stimulating topics that will be discovered and covered over the two full days…

Day 1 – Thursday, 14 September

Clinical immunology: Allergic diseases

  • Pathogenesis of sensitisation
  • Type I and type IV allergies
  • Environmental factors and allergy
  • IgE mediated diseases, mast cell dysfunction and their treatment
  • Contact hypersensitivity
  • Atopic dermatitis
  • IL-4/IL-13 antagonists: How do they work?
  • Desensitisation


Clinical immunology: Autoimmune diseases

  • Antibody-mediated autoimmune diseases: Using pemphigus as a model
  • Cell-mediated autoimmune diseases: Using lichen planus as a model
  • Bullous autoimmune diseases: Why do they look different?
  • TNF and TNF antagonist: How do they work?
  • IL-12 antagonists and T-cell based immunosuppression
  • IL-17/IL-23 and their antagonists: How do they work?
  • B-cell based immunosuppression
  • Intravenous immunoglobulins


Day 2 – Friday, 15 September

Clinical immunology: Auto-inflammatory diseases

  • Definition and spectrum of auto-inflammatory diseases
  • Inflammasome: An intracellular sensor of danger
  • IL-1, IL-1 antagonists and fever syndromes
  • IL-1 family and pustular diseases


Clinical immunology: Immunodeficiencies

  • Primary immune-deficiencies relevant to dermatology
  • Immunodeficiencies in HIV infection
  • Risks of small molecule-immuno-suppressants
  • Infections induced by natalizumab, CTLA-4-Ig, B-cell depletion and related drugs


Clinical immunology: Immunotherapy of infectious diseases

  • Beta-defensins in cutaneous infection
  • Modes of adaptive immunity to infection
  • HPV and zoster vaccines: Mode of action and efficacy
  • Live attenuated and inactivated vaccines: Benefits and risks


Clinical immunology: Immunotherapy of malignant diseases

  • Tumour microenvironment
  • New perspectives for anti-cancer vaccines: Personalisation and combination
  • Exploiting antiviral defense for cancer immunotherapy
  • CTLA4 and PD-1/PD-L1 antagonists: Mode of action


The full programme with confirmed speakers is available for viewing here.

Beware of scams

Please beware of scam companies pretending to offer accommodation and registration to the EADV Congress (adding a percentage of commissions)!

Only trust information from our official websites:




· (to contact the EADV Staff)


You have Successfully Subscribed!

Back to top